https://www.selleckchem.com/pr....oducts/n-formyl-met-
raction and review conduct. Our results can serve as a baseline to assess the uptake of such tools in future analyses. Lasmiditan (LTN) is a selective 5-HT receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment across 4 attacks (CENTURION). Patients were randomized 111 to LTN 200mg (LTN20, LTN100, or a control group that received placebo for 3 attacks and LTN50 for either the 3rd or 4th attack (11).
Like
Comment
Share
